A new study by a US National Institutes of Health (NIH) division has shown an experimental HIV vaccine regimen can trigger antibodies that can neutralise multiple global strains of the virus.

Conducted at the National Institute of Allergy and Infectious Diseases (NIAID), the study involved mice, guinea pigs and monkeys. The researchers are planning to initiate a preliminary human trial in the second half of this year to validate its findings.

The vaccine candidate is based on the structure of a vulnerable site on HIV surface protein, which is an epitope called the HIV fusion peptide, that is leveraged by the virus to enter human cells.

This specific fusion peptide epitope is considered as a ‘promising’ target for a vaccine as its structure is similar in majority of the strains. The human immune system also delivers a strong response against it.

“This elegant study is a potentially important step forward in the ongoing quest to develop a safe and effective HIV vaccine.”

Initially, the team tested a variety of immunogens for their effectiveness to elicit HIV-neutralising antibodies in mice. It was observed that the best immunogen had eight amino acids of the fusion peptide binding to a carrier that triggered a strong immune response.

The researchers then went on to evaluate a combination of this immunogen and HIV spike in mice, and found that antibodies linked to the HIV fusion peptide were able to neutralise around 31% of viruses from a global representative panel of 208 strains.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

They adjusted the vaccine regimen based on these observations and assessed it in guinea pigs and monkeys, where substantial fraction of HIV strains were neutralised.

NIAID director Anthony Fauci said: “This elegant study is a potentially important step forward in the ongoing quest to develop a safe and effective HIV vaccine.”

Currently, the team is trying to enhance the vaccine regimen to achieve more potency and better consistency for outcomes with fewer injections.